Subscribe / Renew
|► Subscribe to our Free Weekly Newsletter|
|home||Welcome, sign in or click here to subscribe.||login|
|print email to a friend reprints add to mydjc|
February 1, 2023
Seattle-based Know Labs, an emerging developer of non-invasive medical diagnostic technology, announced changes to its executive leadership team. Ron Erickson, founder and chairman at Know Labs, was unanimously named chief executive officer by the company's board of directors. Erickson has been with the company and its predecessors for nearly 20 years. He brings 30 years of board, business development, financial and executive leadership experience across multiple industries. Alongside Erickson, Dr. James Anderson continues as Know Labs' chief medical officer, leading all activities related to clinical development. Steve Kent continues as Know Labs' chief product officer, responsible for all initiatives related to product development. Know Labs' Finance and Intellectual Property functions continue to be led by Pete Conley, chief financial officer and SVP, intellectual property. Masanori King Takee was promoted to chief technology officer. In his new role, Takee will continue to lead the company's software engineering, artificial intelligence and machine learning activities. Takee joined Know Labs in 2018 as one of the company's first employees and brings 20 years of experience creating software for technology and healthcare startups. Jessica English joins the Know Labs team as chief marketing officer. She will lead the company's marketing and communications efforts in preparation for a commercial launch. English most recently served as vice president of marketing at NZXT, a PC gaming hardware company. Leo Trautwein, previously Know Labs' chief marketing officer, is now chief commercial officer. In his 25-year multi-disciplinary career, Trautwein served as a strategy consultant, general manager and P&L leader. Trautwein will work alongside Erickson on the day-to-day management of Know Labs to ensure the appropriate initiatives are being executed to bring its Bio-RFID technology through FDA clearance and commercialization.